Anavex projects EMA feedback on Alzheimer's drug by year-end 2025
Q1 2025 Management View CEO Christopher Missling highlighted key updates on the Alzheimer's treatment, blarcamesine. He emphasized the potential of the drug to offer "a scalable treatment alternative ...